Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03870763 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants
A Phase 3 study, sponsored by Biogen.
- Terminated
- Registry status
- Phase 3
- Development phase
- 11
- Enrollment target
NCT03870763 is a Phase 3 study that was terminated before completion, run by Biogen. The registered enrollment target is 11 participants.
The verdict
NCT03870763, a Phase 3 study, was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 11 participants
- Enrollment target
Study Summary
The main objective of the study is to evaluate the efficacy of dimethyl fumarate (Tecfidera) and peginterferon beta-1a (Plegridy), both compared with placebo, in pediatric participants with RRMS. The other objectives of this study are to evaluate the safety and tolerability of dimethyl fumarate and peginterferon beta-1a and to assess the effect of dimethyl fumarate and peginterferon beta-1a, both compared with placebo, on additional clinical and radiological measures of disease activity.
Interventions
- DRUG Placebo
- DRUG Dimethyl Fumarate
- DRUG Peginterferon Beta-1a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2019-03-19 |
| Est. Completion | 2022-07-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03870763
The ClinicalTrials.gov registry entry for NCT03870763 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03870763 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03870763 about?
NCT03870763 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants". The main objective of the study is to evaluate the efficacy of dimethyl fumarate (Tecfidera) and peginterferon beta-1a (Plegridy), both compared with placebo, in pediatric participants with RRMS. The other objectives of this study are to evaluate the safety and tolerability of dimethyl fumarate and ...
What is the current status of trial NCT03870763?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 11 participants. The study started on 2019-03-19. Estimated completion is 2022-07-21.
What interventions are being tested in trial NCT03870763?
The interventions under investigation include: Placebo (DRUG), Dimethyl Fumarate (DRUG), Peginterferon Beta-1a (DRUG).
Who is sponsoring clinical trial NCT03870763?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.